These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 16392155)
41. Prevalence of hyperkalemia in adult patients taking spironolactone and angiotensin converting enzyme inhibitors or angiotensin receptor blockers. Surabenjawong U; Thunpiphat N; Chatsiricharoenkul S; Monsomboon A J Med Assoc Thai; 2013 Aug; 96(8):905-10. PubMed ID: 23991595 [TBL] [Abstract][Full Text] [Related]
42. [The use of aldosterone antagonists in the cardiovascular diseases]. Trzaska E; GumuĊka W; Makulska-Nowak HE Kardiol Pol; 2009 Jun; 67(6):667-71. PubMed ID: 19618325 [No Abstract] [Full Text] [Related]
43. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction? McMurray JJ; Pfeffer MA; Swedberg K; Dzau VJ Circulation; 2004 Nov; 110(20):3281-8. PubMed ID: 15545527 [No Abstract] [Full Text] [Related]
46. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. Pitt B; Remme W; Zannad F; Neaton J; Martinez F; Roniker B; Bittman R; Hurley S; Kleiman J; Gatlin M; N Engl J Med; 2003 Apr; 348(14):1309-21. PubMed ID: 12668699 [TBL] [Abstract][Full Text] [Related]
47. Mineralocorticoid receptor antagonists: their use and differentiation in Japan. Sato A Hypertens Res; 2013 Mar; 36(3):185-90. PubMed ID: 23171954 [TBL] [Abstract][Full Text] [Related]
48. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure. Bauersachs J; Fraccarollo D Minerva Cardioangiol; 2003 Apr; 51(2):155-64. PubMed ID: 12783071 [TBL] [Abstract][Full Text] [Related]
49. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Hayashi M; Tsutamoto T; Wada A; Tsutsui T; Ishii C; Ohno K; Fujii M; Taniguchi A; Hamatani T; Nozato Y; Kataoka K; Morigami N; Ohnishi M; Kinoshita M; Horie M Circulation; 2003 May; 107(20):2559-65. PubMed ID: 12732605 [TBL] [Abstract][Full Text] [Related]
50. Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too. Prescrire Int; 2006 Apr; 15(82):46-9. PubMed ID: 16604728 [TBL] [Abstract][Full Text] [Related]
52. [Effect of aldosterone antagonism in heart failure: pharmacotherapeutic options]. Diercks GF; Overdiek JW; van Veldhuisen DJ Ned Tijdschr Geneeskd; 2001 Feb; 145(5):204-8. PubMed ID: 11219145 [TBL] [Abstract][Full Text] [Related]
53. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure. Barnes BJ; Howard PA Ann Pharmacother; 2005 Jan; 39(1):68-76. PubMed ID: 15590870 [TBL] [Abstract][Full Text] [Related]
54. Do diuretics and aldosterone receptor antagonists improve ventricular remodeling? Pitt B J Card Fail; 2002 Dec; 8(6 Suppl):S491-3. PubMed ID: 12555163 [TBL] [Abstract][Full Text] [Related]
55. Eplerenone for the treatment of cardiovascular disorders. Watanabe M; Krum H Expert Rev Cardiovasc Ther; 2012 Jul; 10(7):831-8. PubMed ID: 22908915 [TBL] [Abstract][Full Text] [Related]
56. Aldosterone blockade in patients with acute myocardial infarction. Pitt B Circulation; 2003 May; 107(20):2525-7. PubMed ID: 12777314 [No Abstract] [Full Text] [Related]